

Filed: March 16, 2023

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVARTIS GENE THERAPIES, INC. & NOVARTIS PHARMACEUTICALS
CORPORATION,
PETITIONERS,
v.

GENZYME CORPORATION,
Patent Owner.

Case IPR2023-00609
U.S. Patent 9,051,542

**PETITIONERS' UPDATED MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, Petitioners Novartis Gene Therapies, Inc., and Novartis Pharmaceuticals Corporation, submit the following updates to its Mandatory Notices.

I. Updated Designation of Lead and Backup Counsel – 37 C.F.R. § 42.8(b)(3)

Petitioners add M. David Weingarten, Cora Holt, and Christopher Weber as additional backup counsel in this proceeding.

Lead Counsel	Back-Up Counsel
John D. Livingstone, Reg. No. 59,613 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 271 17th Street, NW Suite 1400 Atlanta, GA 30363-6209 Tel: 404.653.6449 Fax: 404.653.6444 john.livingstone@finnegan.com	Amanda K. Murphy, Reg. No. 59,387 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 1 London Bridge London, United Kingdom SE1 9BG Tel: 202.408.4000 Fax: 202.408.4400 amanda.murphy@finnegan.com Yieyie Yang, Reg. No. 71,923 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Ave., NW Washington, DC 20001 Tel: 202.216.5170 Fax: 202.408.4400 yieyie.yang@finnegan.com M. David Weingarten, Reg. No. 54,533 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 271 17th Street, NW Suite 1400

Lead Counsel	Back-Up Counsel
	Atlanta, GA 30363-6209 Tel: 404.653.6457 Fax: 404.653.6444 m.david.weingarten@finnegan.com Cora Holt, Reg. No. 68,332 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Ave., NW Washington, DC 20001 Tel: 202.408.4334 Fax: 202.408.4400 cora.holt@finnegan.com Christopher Weber, Reg. No. 73,543 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Ave., NW Washington, DC 20001 Tel: 202.408.4432 Fax: 202.408.4400 christopher.weber@finnegan.com

II. Updated Service Information – 37 C.F.R. § 42.8(b)(4)

Please address correspondence to counsel at the addresses above and Novartis-Zolgensma-542IPR@finnegan.com. Petitioners consent to service by e-mail.

Respectfully Submitted

Date: March 16, 2023

By: /John D. Livingstone /
John D. Livingstone
Reg. No. 59,613

*Lead Counsel for Petitioners Novartis Gene
Therapies, Inc., and Novartis
Pharmaceuticals Corporation*

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on March 16, 2023, a copy of the foregoing **PETITIONERS' UPDATED MANDATORY NOTICES UNDER 37 C.F.R. § 42.8** was served via e-mail on counsel of record for the Patent Owner at the following addresses:

Paul H. Berghoff
McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive, 32nd Floor
Chicago, IL 60606
Email: berghoff@mbhb.com

James L. Lovsin
McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive, 32nd Floor
Chicago, IL 60606
Email: lovsin@mbhb.com

Dmitriy A. Vinarov
McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive, 32nd Floor
Chicago, IL 60606
Email: vinarov@mbhb.com

Patent Owner has agreed to electronic service.

Dated: March 16, 2023

By: /Lauren K. Young/
Lauren K. Young
Litigation Legal Assistant
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.